Emodin-6-O-β-d-glucoside down-regulates endothelial protein C receptor shedding

Archives of Pharmacal Research

Volumn 36, Issue 9, 2013, Pages 1160-1165

  Lee, Wonhwa ^a,b   Ku, Sae Kwang ^c   Bae, Jong Sup ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Daegu Haany University   (South Korea)

Author keywords

Emodin 6 O d glucoside; EPCR; PMA; Shedding

Indexed keywords

EMODIN 6 O BETA D GLUCOSIDE; ENDOTHELIAL PROTEIN C RECEPTOR; PHORBOL 13 ACETATE 12 MYRISTATE; POLYGONUM CUSPIDATUM EXTRACT; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; LIGATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PUNCTURE; SEPTICEMIA; UMBILICAL VEIN ENDOTHELIAL CELL;

ADAM PROTEINS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EMODIN; ENDOTHELIUM, VASCULAR; GLUCOSIDES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; RECEPTORS, CELL SURFACE; SEPSIS; SOLUBILITY;

EID: 84884208387     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0114-6     Document Type: Article

References (30)

1. Aggarwal, B.B.; H. Ichikawa, P. Garodia, P. Weerasinghe, G. Sethi, I.D. Bhatt, M.K. Pandey, S. Shishodia, and M.G. Nair. 2006. From traditional ayurvedic medicine to modern medicine: Identification of therapeutic targets for suppression of inflammation and cancer. Expert Opinion on Therapeutic Targets 10: 87-118.
2. Bae, J.S. 2012. Role of high mobility group box 1 in inflammatory disease: Focus on sepsis. Archives of Pharmacal Research 35: 1511-1523.
3. Bae, J.S.; and A.R. Rezaie. 2011. Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood 118: 3952-3959.
4. Bae, J.S.; L. Yang, and A.R. Rezaie. 2007. Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 104: 2867-2872.
5. Buras, J.A.; B. Holzmann, and M. Sitkovsky. 2005. Animal models of sepsis: Setting the stage. Nature Reviews. Drug Discovery. 4: 854-865.
6. Esmon, C.T. 2006. The endothelial protein C receptor. Current Opinion in Hematology 13: 382-385.
7. Fukudome, K.; and C.T. Esmon. 1994. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. Journal of Biological Chemistry 269: 26486-26491.
8. Fukudome, K.; S. Kurosawa, D.J. Stearns-Kurosawa, X. He, A.R. Rezaie, and C.T. Esmon. 1996. The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. Journal of Biological Chemistry 271: 17491-17498.
9. Guitton, C.; N. Gerard, V. Sebille, C. Bretonniere, O. Zambon, D. Villers, and B. Charreau. 2011. Early rise in circulating endothelial protein C receptor correlates with poor outcome in severe sepsis. Intensive Care Medicine 37: 950-956.
10. Han, H.; B. Du, X. Pan, J. Liu, Q. Zhao, X. Lian, M. Qian, and M. Liu. 2010. CADPE inhibits PMA-stimulated gastric carcinoma cell invasion and matrix metalloproteinase-9 expression by FAK/MEK/ERK-mediated AP-1 activation. Molecular Cancer Research 8: 1477-1488.
11. Kim, D.C.; W. Lee, and J.S. Bae. 2011. Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro. Inflammation Research 60: 1161-1168.
12. Kim, T.H.; S.K. Ku, I.C. Lee, and J.S. Bae. 2012. Anti-inflammatory functions of purpurogallin in LPS-activated human endothelial cells. BMB Reports 45: 200-205.
13. Kimura, Y.; H. Okuda, and M. Kubo. 1995. Effects of stilbenes isolated from medicinal plants on arachidonate metabolism and degranulation in human polymorphonuclear leukocytes. Journal of Ethnopharmacology 45: 131-139.
14. Kurosawa, S.; D.J. Stearns-Kurosawa, C.W. Carson, A. D'Angelo, P. Della Valle, and C.T. Esmon. 1998. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 91: 725-727.
15. Kurosawa, S.; D.J. Stearns-Kurosawa, N. Hidari, and C.T. Esmon. 1997. Identification of functional endothelial protein C receptor in human plasma. Journal of Clinical Investigation 100: 411-418.
16. Lee, W.; S.K. Ku, T.H. Kim, and J.S. Bae. 2013. Emodin-6-O-beta-d- glucoside inhibits HMGB1-induced inflammatory responses in vitro and in vivo. Food and Chemical Toxicology 52: 97-104.
17. Leng, Y.; T.L. Steiler, and J.R. Zierath. 2004. Effects of insulin, contraction, and phorbol esters on mitogen-activated protein kinase signaling in skeletal muscle from lean and ob/ob mice. Diabetes 53: 1436-1444.
18. Liaw, P.C.; P.F. Neuenschwander, M.D. Smirnov, and C.T. Esmon. 2000. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. Journal of Biological Chemistry 275: 5447-5452.
19. Lopez-Sagaseta, J.; R. Montes, C. Puy, N. Diez, K. Fukudome, and J. Hermida. 2007. Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity. Journal of Thrombosis and Haemostasis 5: 1817-1824.
20. Menschikowski, M.; A. Hagelgans, G. Eisenhofer, and G. Siegert. 2009. Regulation of endothelial protein C receptor shedding by cytokines is mediated through differential activation of MAP kinase signaling pathways. Experimental Cell Research 315: 2673-2682.
21. Mosnier, L.O.; B.V. Zlokovic, and J.H. Griffin. 2007. The cytoprotective protein C pathway. Blood 109: 3161-3172.
22. Qu, D.; Y. Wang, N.L. Esmon, and C.T. Esmon. 2007. Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17. Journal of Thrombosis and Haemostasis 5: 395-402.
23. Qu, D.; Y. Wang, Y. Song, N.L. Esmon, and C.T. Esmon. 2006. The Ser219->Gly dimorphism of the endothelial protein C receptor contributes to the higher soluble protein levels observed in individuals with the A3 haplotype. Journal of Thrombosis and Haemostasis 4: 229-235.
24. Regan, L.M.; D.J. Stearns-Kurosawa, S. Kurosawa, J. Mollica, K. Fukudome, and C.T. Esmon. 1996. The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. Journal of Biological Chemistry 271: 17499-17503.
25. Saposnik, B.; E. Peynaud-Debayle, A. Stepanian, G. Baron, M. Simansour, L. Mandelbrot, D. de Prost, and S. Gandrille. 2012. Elevated soluble endothelial cell protein C receptor (sEPCR) levels in women with preeclampsia: A marker of endothelial activation/damage? Thrombosis Research 129: 152-157.
26. Saposnik, B.; J.L. Reny, P. Gaussem, J. Emmerich, M. Aiach, and S. Gandrille. 2004. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 103: 1311-1318.
27. Stearns-Kurosawa, D.J.; S. Kurosawa, J.S. Mollica, G.L. Ferrell, and C.T. Esmon. 1996. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proceedings of the National Academy of Sciences of the United States of America 93: 10212-10216.
28. Wang, H.; H. Liao, M. Ochani, M. Justiniani, X. Lin, L. Yang, Y. Al-Abed, C. Metz, E.J. Miller, K.J. Tracey, and L. Ulloa. 2004. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nature Medicine 10: 1216-1221.
29. Xu, J.; D. Qu, N.L. Esmon, and C.T. Esmon. 2000. Metalloproteolytic release of endothelial cell protein C receptor. Journal of Biological Chemistry 275: 6038-6044.
30. Yang, H.; M. Ochani, J. Li, X. Qiang, M. Tanovic, H.E. Harris, S.M. Susarla, L. Ulloa, H. Wang, R. DiRaimo, C.J. Czura, J. Roth, H.S. Warren, M.P. Fink, M.J. Fenton, U. Andersson, and K.J. Tracey. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America 101: 296-301.